AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33559351
Drug: Stryphnodendron adstringens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stryphnodendron adstringens (SA) at 300 mg/L
Trial: 33559351
Drug: Lafoensia pacari
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafoensia pacari (LP) at 30 mg/L
Trial: 32960320
Drug: Selective retina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective retina therapy (SRT)
Trial: 34377137
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora (ZM) extract syrup
Trial: 32643674
Drug: SGB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB with 10 mL of 0.5% bupivacaine (Group B)
Trial: 33818314
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy group (LLLT)
Trial: 35837981
Drug: TOTUM-63 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOTUM-63 (5 g/day)
Trial: 35213728
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users
Trial: 33735707
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment for 16 weeks
Trial: 33735707
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 16 weeks
Trial: 32798835
Drug: Food-related behavioral
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-related behavioral activation therapy (F-BA)
Trial: 34903983
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (HSS) 150 mL
Trial: 34903983
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 150 mL
Trial: 34903983
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 250 mg IV furosemide every 12 h for 48 h
Trial: 32487038
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiation (SABR) + radium-223 dichloride (6 infusions at 4-week intervals)
Trial: 34556166
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous iron (two different formulations) administered early in the second trimester
Trial: 34556166
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of oral iron
Trial: 34556166
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous iron (two different formulations)
Trial: 32880105
Drug: Phenytoin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (300 mg/day)
Trial: 33491093
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser‐mediated photodynamic therapy
Trial: 33491093
Drug: Conventional red‐light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional red‐light photodynamic therapy
Trial: 36380126
Drug: Early withdrawal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early withdrawal of life-sustaining treatments based on presumed poor neurologic prognosis (WLST-N)
Trial: 36380126
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of sedative medications in patients with early WLST-N
Trial: 32641081
Drug: Preoperative immunonutrition
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative immunonutrition (400 mL/day with arginine and ω‐3 fatty acids for 7 days)
Trial: 34942330
Drug: Multivitamin/Mineral Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/Mineral Supplement (MVM)
Trial: 34942330
Drug: No study‐provided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study‐provided supplements
Trial: 34229859
Drug: Morphine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.02 mg.kg‐1.h‐1)
Trial: 34229859
Drug: Fentanyl (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.3 mcg.kg‐1.h‐1)
Trial: 34229859
Drug: Both Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Morphine and Fentanyl
Trial: 32343918
Drug: Subcutaneous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous lidocaine infusion (SCLI) at a dosage of 10 mg/kg over 5.5 hours
Trial: 35210767
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics prescribed in the prior 12 months
Trial: 35871473
Drug: Topical 4%
RxNorm normalized name: menthol topical 4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4% sucralfate cream four times a day for 2 months
Trial: 34508901
Drug: Atomoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (40 mg)
Trial: 34882608
Drug: Novel combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel combination of omega‐3 and omega‐6 fatty acids (1200 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 150 mg γ‐linoleic acid)
Trial: 34882608
Drug: Novel combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel combination of omega‐3 and omega‐6 fatty acids
Trial: 32779011
Drug: GC dry
RxNorm normalized name: ARTIFICIAL SALIVA GC DRY MOUTH DENT GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC dry mouth gel (GC)
Trial: 32444040
Drug: Aq+ (3056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aq+ (3056 mg day-1)
Trial: 32444040
Drug: Glu (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glu (2000 mg day-1)
Trial: 34868084
Drug: Leronlimab (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (weekly 700 mg)
Trial: 34868084
Drug: Leronlimab (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (weekly treatment)
Trial: 32901330
Drug: Fruquintinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib (5 mg once daily for 3 weeks, followed by 1 week off in 28-day cycles)
Trial: 35343430
Drug: New sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sodium valproate formulation (epilenil 500‐mg coated tablet)
Trial: 35343430
Drug: Depakene formulation
RxNorm normalized name: Depakote
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depakene formulation
Trial: 33118638
Drug: Integrative Cognitive‐Affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Cognitive‐Affective Therapy for BED
Trial: 33118638
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy delivered using guided self‐help
Trial: 33619171
Drug: m276-SL-PBD (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m276-SL-PBD (0.5 mg/kg on days 1, 8, and 15)
Trial: 33619171
Drug: m276-SL-PBD (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m276-SL-PBD (single 0.5 mg/kg dose)
Trial: 37090440
Drug: Moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg)
Trial: 37495276
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin monotherapy (rosuvastatin 20 mg)
Trial: 37978309
Drug: Moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity statin with ezetimibe combination therapy
Trial: 36529993
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin monotherapy
Trial: 35780241
Drug: Weekly educational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly educational one-way text messages on sexo-reproductive health
Trial: 32427354
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Trial: 32427354
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Trial: 33308274
Drug: Capsaicin application
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin application (depth and dose not specified)
Trial: 33308274
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control treatment groups)
Trial: 33516143
Drug: KXS 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KXS 3.2 g/day
Trial: 35022282
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice daily plus FOLFIRI regimen (5-fluorouracil, leucovorin, irinotecan)
Trial: 34899124
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy (biofeedback training)
Trial: 35589610
Drug: Ladarixin (LDX)
RxNorm normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ladarixin (LDX) 400 mg twice-daily for three cycles of 14 days on/14 days off
Trial: 33130034
Drug: Control (HICT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (HICT performed twice at baseline and end)
Trial: 39539565
Drug: Aquablation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquablation therapy
Trial: 32200225
Drug: Treatment targeting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment targeting reductions in negative affect or increases in positive affect (15 sessions)
Trial: 33942327
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy (CPT), median volume of 828 ml (range: 817–960), administered 14 days after ICU admission.
Trial: 34930267
Drug: Cipargamin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin (10 to 150 mg single doses and 10 to 50 mg once daily for 3 days)
Trial: 36905719
Drug: Mevidalen 10
RxNorm normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen 10 mg
Trial: 36905719
Drug: Mevidalen 30
RxNorm normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen 30 mg
Trial: 36905719
Drug: Mevidalen 75
RxNorm normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen 75 mg
Trial: 33523774
Drug: Budesonide intranasal
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide intranasal formulation with charcoal block
Trial: 33523774
Drug: Budesonide intranasal
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide intranasal formulation without charcoal block
Trial: 32073622
Drug: Manual pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual pill counting using a plastic dish and spatula
Trial: 32073622
Drug: Efforts put
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efforts put into pill counting
Trial: 32073622
Drug: Interventions alleviating
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions alleviating the burden of pill counting
Trial: 33673587
Drug: Almonds (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds (20% of daily energy consumption)
Trial: 32391667
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg per day for 5 days plus conventional treatments
Trial: 34229330
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor resistance
Trial: 35579297
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion at a rate of 125 mL/h
Trial: 35579297
Drug: 1/3-2/3 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/3-2/3 infusion at a rate of 125 mL/h
Trial: 35579297
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate infusion at a rate of 125 mL/h
Trial: 36096824
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (350 mg elemental magnesium/day)
Trial: 36096824
Drug: Phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate binder sucroferric oxyhydroxide (1000 mg/day)
Trial: 33979464
Drug: Xiyanping injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xiyanping injection in combination with standard therapy
Trial: 33979464
Drug: Standard supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supportive therapy alone
Trial: 34288256
Drug: Glide-path preparation
RxNorm normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glide-path preparation
Trial: 34485157
Drug: Endostar continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar continuous intravenous infusion of anti‐angiogenic therapy plus CCRT
Trial: 34485157
Drug: Radiotherapy for
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy for cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT)
Trial: 32600386
Drug: radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: radial extracorporeal shock wave therapy (rESWT)
Trial: 34080077
Drug: Oral danirixin
RxNorm normalized name: Danirixin
DrugBank: Danirixin (DB11922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral danirixin 75 mg twice daily
Trial: 32473084
Drug: Topical active
RxNorm normalized name: collagen,activated Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical active lotion (Redensyl and Sepicontrol A5), applied twice daily for 24 weeks
Trial: 32473084
Drug: Vehicle control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control, applied twice daily for 24 weeks
Trial: 36269028
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine + 0.5 mg/ml 0.02% oestradiol compound cream + oral placebo pill
Trial: 36269028
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant nortriptyline + placebo cream
Trial: 36269028
Drug: Combined peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined peripheral cream and central pill treatments
Trial: 36269028
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream and placebo pill
Trial: 33150360
Drug: Truncated asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truncated asparaginase treatment due to clinical toxicity (n = 358)
Trial: 33150360
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without truncation (n = 1043)
Trial: 33150360
Drug: Truncated asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truncated asparaginase treatment or silent inactivation (n = 301)
Trial: 35614156
Drug: Losartan ointment
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan ointment
Trial: 33651470
Drug: Water-soluble herbal
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble herbal acne patch (WHAP)
Trial: 33651470
Drug: Hydrocolloid acne
RxNorm normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid acne patch (HAP)
Trial: 33182295
Drug: Pre-workout supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-workout supplement
Trial: 33725178
Drug: VC+ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC+ group (500 mg/day PO for 45 days postoperatively)
Trial: 32299454
Drug: Combined extracorporeal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined extracorporeal shock wave lithotripsy (ESWL) and endoscopic treatment
Trial: 32299454
Drug: Combined ESWL
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ESWL and endoscopic treatment
Trial: 36027559
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg once daily)
Trial: 32443298
Drug: low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose recombinant tissue plasminogen activator (rt-PA)
Trial: 35490744
Drug: Lenabasum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum (20 mg daily for 28 days, then 20 mg twice per day for 56 days)
Trial: 38160885
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment for 4 weeks
Trial: 32725069
Drug: Fungicide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fungicide treatment FT1 (pyraclostrobin + fluxapyroxad)
Trial: 32725069
Drug: Fungicide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fungicide treatment FT2 (trifloxystrobin + prothioconazole)
Trial: 34333889
Drug: Guided Self-Determination
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Self-Determination (GSD) intervention with weekly sessions for eight weeks
Trial: 35813843
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg/b.m.)
Trial: 32133542
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy using clay peloid mixed with tap water and heliotherapy (group 2)
Trial: 35538143
Drug: anthracycline/taxane‐based NACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anthracycline/taxane‐based NACT plus metformin
Trial: 35725488
Drug: 2-dose Ebola
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo)
Trial: 32178279
Drug: EPA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-rich fish oil (12 g/day, EPA/DHA: 2.3)
Trial: 32178279
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (12 g/day, EPA/DHA: 0.3)
Trial: 35398293
Drug: Daily teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily teriparatide (20 μg)
Trial: 35398293
Drug: Weekly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly high-dose teriparatide (56.5 μg)
Trial: 35287618
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid (TXA) 15 minutes before surgery
Trial: 33577729
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin (1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle)
Trial: 33577729
Drug: Chemotherapy (investigator-chosen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator-chosen standard docetaxel, paclitaxel, or vinflunine on day 1 of a 21-day cycle)
Trial: 38182785
Drug: Ripretinib 150
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib 150 mg once daily
Trial: 37598656
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Trial: 36382669
Drug: 0.025% capsaicin
RxNorm normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% capsaicin gel with topical anesthetic
Trial: 36382669
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic monotherapy
Trial: 34037975
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose solution (2 ml)